Abstract
Solid organ transplant recipients are at an increased risk of tuberculosis and transplant candidates should be screened early in their evaluation with a detailed history, tuberculin skin test or tuberculosis interferon-gamma release assay, and chest radiograph. For latent tuberculosis treatment, isoniazid and rifamycin-based regimens have advantages and disadvantages; treatment decisions should be customized. Tuberculosis after solid organ transplantation generally occurs after months or years; early infections should raise the possibility of donor-derived infections. Tuberculosis diagnosis and treatment in solid organ transplant recipients may be complicated by protean manifestations, drug interactions, and adverse drug reactions.
Citations
Sep 2, 2019·Current Infectious Disease Reports·Michele I Morris, Elmi Muller
Jul 4, 2020·Current Opinion in Organ Transplantation·Jean Gibb, Darren Wong
Jul 9, 2020·JAMA Dermatology·David M SchauderRajiv I Nijhawan
Jul 26, 2019·World Journal of Gastroenterology : WJG·Jose Tiago SilvaJosé María Aguado
Sep 23, 2020·Transplant Infectious Disease : an Official Journal of the Transplantation Society·A Gomila-GrangeM Santin
Jan 29, 2021·Global Pediatric Health·Melanie DuboisGabriella Lamb
Apr 10, 2021·Jornal brasileiro de nefrologia : ʹorgão oficial de Sociedades Brasileira e Latino-Americana de Nefrologia·Luiz Roberto de Sousa UlissesGustavo de Sousa Arantes Ferreira
May 8, 2021·Case Reports in Transplantation·Wanessa T ClementeMarcelo Dias Sanches
May 18, 2021·Jornal brasileiro de nefrologia : ʹorgão oficial de Sociedades Brasileira e Latino-Americana de Nefrologia·Gisele MeinerzElizete Keitel
Mar 23, 2020·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Christianne BourlonAlfredo Ponce-de-León
Jul 11, 2019·Current Opinion in Organ Transplantation·Deepa D Nanayakkara, Joanna Schaenman
Sep 11, 2021·Transplant Infectious Disease : an Official Journal of the Transplantation Society·Da Eun KwonKyoung Hwa Lee